Department of Rehabilitation, School of Nursing, Jilin University, Changchun, China.
Department of Pharmacy, Tacheng People's Hospital, Tacheng City, Xinjiang Uygur Autonomous Region, China.
Front Immunol. 2023 Dec 14;14:1310130. doi: 10.3389/fimmu.2023.1310130. eCollection 2023.
Antibody-cell conjugation (ACC) technology is a new research direction in medicine and biotechnology in recent years. The concept of ACC was proposed by Hsiao et al. and developed into a viable cell therapy technology, which refers to the cells with specific functions. Such as natural killer cells (NK cells), cytokine induced killer cells (CIK) and other immune cells and monoclonal antibodies through the linker together formed conjugate. ACC directly modifies specific antibodies on the cell surface through a simple and effective chemical coupling method to enable cells to have new functions. ACC has been developed for the treatment of various diseases, including cancers of the blood system and solid tumors. This paper reviews the current ACC construction methods, challenges and future development directions.
抗体-细胞偶联 (ACC) 技术是近年来医学和生物技术领域的一个新的研究方向。ACC 的概念是由 Hsiao 等人提出的，并发展成为一种可行的细胞治疗技术，它是指具有特定功能的细胞，如自然杀伤细胞 (NK 细胞)、细胞因子诱导的杀伤细胞 (CIK) 和其他免疫细胞与单克隆抗体通过连接子连接在一起形成偶联物。ACC 通过一种简单有效的化学偶联方法直接修饰细胞表面的特异性抗体，使细胞具有新的功能。ACC 已被开发用于治疗各种疾病，包括血液系统癌症和实体瘤。本文综述了目前的 ACC 构建方法、面临的挑战和未来的发展方向。
